TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Peripheral and hepatic insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Persistence of severity of SAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSS score changes after TKA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KSS score changes after TKA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength measurement changes after TKA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to perception of sweetness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of SBRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reflux events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Procedure and Device-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Successful delivery of the EAST System into the AAA sac
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Peak Joint Powers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Ground Reaction Forces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50 Meter Dash
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GERD occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Community-level PCR-based P. falciparum prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HS-RDT-based test positivity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Community-level confirmed P. falciparum malaria parasite incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diffusion tensor imaging of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of relatives with IES score > 30
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post Treatment Serum Cortisol Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Graft-versus-host Disease Free Relapse Free (GRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of MSI-H
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With HIV Plasma Viral Load Below Detection Limit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival with favorable neurological function
Endpoint domain: Mortality/survival
Primary endpoint: recurrence rate of severe prolapsed Hemorrhoids after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Peak ∆ serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AKI ≥stage2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Modified Mayo Score indicating remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TEG values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Remethylation of Homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Flux of Homocysteine Remethylation From Serine-derived Carbon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting Plasma Pyridoxal Phosphate Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting Plasma Cystathionine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PTSD Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of binge drinking days
Endpoint domain: Life impact
Endpoint subdomain: Substance use
Primary endpoint: Accuracy of mHRME to detect CIN2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline Visual Acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone change in millimeters from initial to full healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cone beam computed tomography bone density changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of bone formation in the alveolar bone core biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue pain scale for low back pain (LBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale for radiculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EuroQol questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oswestry questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients with new vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Hospital Anxiety and Depression Scale - Anxiety Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Altman Self-Rating Mania Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plaque Score change at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque Score change at 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding Score change at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding Score change at 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASI 75% Improvement From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of Sperm Production ≤1 Million/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in long-term care plan decision-making
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Daily Net Fluid Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute hemodynamic effect (LV dP/dtmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in left ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antibiotic misuse
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective Unit of Discomfort Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Platelet reactivity at Hour 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ocular Itching Post-CAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival Redness Post-CAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving ACR50 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Complete and partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate of 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Related Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With aTTP Related Deaths Reported During the Study
Endpoint domain: Mortality/survival
Primary endpoint: Health-Related Quality of Life (HRQoL): Change From Baseline in Headache Impact Test (HIT-6) Total Scores at Month 12, 24, and 36 Follow-up Visits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: steroid-free endoscopic remission or response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Primary Eyes Requiring Peripheral Iridotomy (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Endothelial Cell Density (ECD) Change in Primary Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Ocular Adverse Events (AEs) in Primary Eyes
Endpoint domain: Adverse events/effects
Primary endpoint: 2-year Disease-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Regression at 60 weeks postmenstrual age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gas trapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Levodopa-induced dyskinesia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Satisfaction with the health coach intervention (surveys)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with the health coach intervention (phone interviews)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 10 Meter Walk Test (10MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Success Rate (Subject's Global Assessment of 'Clear' or 'Almost Clear')
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients With Objective Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Any grade 3 solicited symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) diagnosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction of Xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of imminent spontaneous preterm delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Changes in bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Health Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Montreal Cognitive Assessment (MOCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Free and Cued Selective Reminding Test (FCSRT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: number of patients with genetic polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of Antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Days of antimicrobial treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Regional brain beta amyloid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional brain serotonin terminal density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Minimal residual disease negativity after first line treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Measure of Humoral Immune Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antigen specific CD4+ and CD8+ T-cell reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measure of Tumor Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Colorectal Cancer Stage (pTNM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of cesarean scar defect (niche)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Glucose Trafficking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IPSS response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Variability of Intracranial Pressure (ICP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Pressure Reactivity Index (PRx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in NRS-Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Relapse-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Safety of neural stem cell transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Treatment-related Adverse Events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in MRI study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth velocity of weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microbial diversity in the intestinal microbiomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete Response Rate at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Experiencing an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Discontinuing Study Treatment Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of adipose derived stem cells
Endpoint domain: Adverse events/effects
Primary endpoint: Risk Perceptions for Colorectal Cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intentions to Screen for Colorectal Cancer
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Information Seeking Behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Recurrent upper gastro-intestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Exercise Pressor Reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose of AZD 2461
Endpoint domain: Adverse events/effects
Primary endpoint: hematology data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: clinical chemistry data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroretinogram responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pre-ejection period (PEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Subjects With an sUA Level < 6.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time-to-healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum nickel levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic Geometric Center at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in pain-related fear level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of sTREM-1 in fine needle aspiration fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Reflective Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythroid response in non-transfusion dependent patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Erythroid response in transfusion-dependent patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of adverse events related to tipifarnib
Endpoint domain: Adverse events/effects
Primary endpoint: WBC response (complete and partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Work and Activities (HAMD-24 Item 7)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement in the eczema status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in the frequency and severity of infection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the frequency and severity of bruising and bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the frequency and severity of autoimmune disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the number of disease related days of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: chronic critical illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity/Mortality related to PKU false positives
Endpoint domain: Mortality/survival
Primary endpoint: Tumor diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of lymph nodes dissected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of metastatic lymph nodes diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: self rated quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: complete disappearance of the chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eosinophils activation and phagocyte system function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evolution to more severe forms of the disease
Endpoint domain: Mortality/survival
Primary endpoint: Number of uncomplicated examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial grimacing assessed by brow bulge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total body fat%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Early Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Return rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quantification of CD20 and PDL-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in PDQ-39 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence and severity of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the effect curve (AUEC) for serum aldosterone and PRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical benefit rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of High-Grade Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum intra-tumoural pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour response 3 months post-radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: secretion wet weight (gram)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: viscosity of secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization frequency change
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Pneumonia aspiration frequency change
Endpoint domain: Adverse events/effects
Primary endpoint: Seizure Frequency change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Route of feeding change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Foveal and Pericentral Pigment Optical Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Subfoveal, Temporal and Nasal Choroidal Thicknesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Anterior Chamber Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Iridocorneal Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell immunity response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Excretion of 14C (mass balance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes